The glasgow prognostic score (gps) as a novel and significant predictor of extranodal natural killer/t-cell lymphoma, nasal type

American Journal of Hematology

Volumn 88, Issue 5, 2013, Pages 394-399

  Li, Ya Jun ^a   Jiang, Wen Qi ^a   Huang, Jia Jia ^a   Xia, Zhong Jun ^a   Huang, Hui Qiang ^a   Li, Zhi Ming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; INFLAMMATION; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHINA; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TUMOR BURDEN; YOUNG ADULT;

EID: 84876732021     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23422     Document Type: Article

References (35)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
2. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113:3931-3937.
3. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: Long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004;103:216-221.
4. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: A single institute survey in Taiwan. Ann Oncol 2004;15:618-625.
5. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612-618.
6. Huang JJ, Jiang WQ, Lin TY, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 2011;22:149-155.
7. Marnell L, Mold C, Du Clos TW. C-reactive protein: Ligands, receptors and role in inflammation. Clin Immunol 2005;117:104-111.
8. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009;12:223-226.
9. Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003;89:1028-1030.
10. Forrest LM, McMillan DC, McArdle CS, et al. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004;90:1704-1706.
11. Crumley AB, McMillan DC, McKernan M, et al. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 2006;94:637-641.
12. Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 2007;97:1266-1270.
13. Ramsey S, Lamb GW, Aitchison M, et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007;109:205-212.
14. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011;47:2633-2641.
15. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
16. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-2479.
17. Gage JR, Fonarow G, Hamilton M, et al. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation 2004;11:173-180.
18. Gortney JS, Sanders RM. Impact of C-reactive protein on treatment of patients with cardiovascular disease. Am J Health Syst Pharm 2007;64:2009-2016.
19. Koukourakis MI, Kambouromiti G, Pitsiava D, et al. Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. Inflammation 2009;32:169-175.
20. Lee CC, Adler AI, Sandhu MS, et al. Association of C-reactive protein with type 2 diabetes: Prospective analysis and meta-analysis. Diabetologia 2009;52:1040-1047.
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
22. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001;357:539-545.
23. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444.
24. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-899.
25. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005;23:2078-2093.
26. Seymour JF, Talpaz M, Cabanillas F, et al. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995;13:575-582.
27. Legouffe E, Rodriguez C, Picot MC, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 1998;31:351-357.
28. Giachelia M, Voso MT, Tisi MC, et al. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kappaB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2012;53:411-416.
29. Yang J, Wezeman M, Zhang X, et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 2007;12:252-265.
30. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J 2010;9:69.
31. Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004;104:243-249.
32. Kim HS, Kim KH, Chang MH, et al. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: Extranodal natural killer/T-cell lymphoma. Leuk Lymphoma 2009;50:757-763.
33. Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 2011;118:6018-6022.
34. Ito Y, Kimura H, Maeda Y, et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. Clin Cancer Res 2012;18:4183-4190.
35. Wang ZY, Liu QF, Wang H, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood 2012;120:2003-2010.